1. Introduction {#sec1-antibiotics-09-00219}
===============

The bibliometric analysis provides a quantitative review of literature in any field of research based on the citation frequency of the conducted research. This type of analysis identifies the countries, organizations, and authors who were affiliated with the most prominent scientific contributions \[[@B1-antibiotics-09-00219],[@B2-antibiotics-09-00219]\]. The thrust areas of the past research in a specialty can be identified by analyzing the most-cited work currently, which information can then be used to channel the future research.

The bibliometric concept of "citation classics" was described by the founder of the Institute for Scientific Information (ISI), Dr Eugene Garfield, in 1977. Its purpose was identification as well as acknowledgment of frequently cited research of authors and their peers that would consequently encourage the respective work and its impact on the specialty \[[@B3-antibiotics-09-00219]\]. The eligibility of a scientific contribution to be counted as a "classic" depends on the specialty being analyzed. While some analysts believe that 100 or more citations of a publication are sufficient \[[@B4-antibiotics-09-00219],[@B5-antibiotics-09-00219],[@B6-antibiotics-09-00219],[@B7-antibiotics-09-00219]\], others believe that a publication must be cited more than 400 times to be counted in the list \[[@B8-antibiotics-09-00219]\]. Leading scientific databases like Web of Science (WoS), Elsevier's Scopus (ES), and Google Scholar (GS) and influential publishers like BioMed Central, Nature, Wiley, Frontiers, Elsevier, and PLOS are developing and embedding options to perform on-site citation analysis \[[@B4-antibiotics-09-00219],[@B8-antibiotics-09-00219],[@B9-antibiotics-09-00219],[@B10-antibiotics-09-00219],[@B11-antibiotics-09-00219]\].

Several bibliometric analyses have been conducted in other fields of health sciences, which include the specialty of dentistry \[[@B4-antibiotics-09-00219],[@B8-antibiotics-09-00219],[@B9-antibiotics-09-00219],[@B12-antibiotics-09-00219],[@B13-antibiotics-09-00219]\] and medicine \[[@B14-antibiotics-09-00219],[@B15-antibiotics-09-00219],[@B16-antibiotics-09-00219],[@B17-antibiotics-09-00219],[@B18-antibiotics-09-00219]\]. However, the "classics" in the field of antibiotics has not been identified. The aim is to identify and analyze the top 100 classics in the specialty of antibiotics to highlight the notable advancements made on this very topic over the recent decades.

2. Materials and Methods {#sec2-antibiotics-09-00219}
========================

2.1. Search Strategy {#sec2dot1-antibiotics-09-00219}
--------------------

Two independent reviewers (A.I.A) and (P.A) conducted a literature search on 21st March 2020 using 'All-Databases' collection of WoS. The search terms were identified after consulting field experts from different institutions, and a final search string was developed and agreed upon unanimously. No language restrictions, publication year range, or methodology selections were applied.

2.2. Eligibility Criteria {#sec2dot2-antibiotics-09-00219}
-------------------------

Titles of the articles published in peer-reviewed journals were selected when either of the following search terms identified: "antibiotics" OR "antibiotic" OR "anti-bacterial" OR "antibacterial" OR "anti-infective" OR "anti-infectious" OR "anti-microbial" OR "antimicrobial".

Articles having less than 400 citations according to the WoS and ES databases were excluded. Articles published in low or no impact factor journals were not included in the marked list.

2.3. Data Extraction and Bibliometric Parameters {#sec2dot3-antibiotics-09-00219}
------------------------------------------------

A total of 124,122 publications were initially identified using the search string described above. The publications were sorted based on the frequency of citations in a descending manner. The list of top 100 classics was marked based on the citation frequency. The marked list was then cross-matched with GS and ES databases. The marked lists from the A.I.A and P.A was then shared with the field experts, and all authors unanimously agreed upon the final list. Bibliometric parameters for the articles available in "All Databases" were recorded from the WoS database, which includes the title of the article, journal title, citation count, current citation index (CCI) 2019 (total citations received in 2019), publication year, names of authors along with their affiliated organizations, and country of origin. Each publication was then hand-searched to identify evidence level, keywords, and the methodology of the study. The missing data was then cross-matched with the ES database to ensure the accuracy and correctness of collected information.

2.4. Methodological Design {#sec2dot4-antibiotics-09-00219}
--------------------------

The publications were then categorized according to the methodology of the study as review articles, expert opinion, clinical practice guidelines, cross-sectional study, new material or technique, clinical studies, and laboratory studies.

2.5. Institution and Country of Origin {#sec2dot5-antibiotics-09-00219}
--------------------------------------

The author's affiliation and origin country of publication were retrieved from the ES database as complete information for the marked list was not available from the WoS database. The retrieved information was then hand-searched and compared with the original text for each manuscript. Although corresponding addresses are considered a reliable source to identify the country of origin of publication; however, upon searching manually, it was seldom recorded. Each institution contributing to the publication was recorded as a single entry.

2.6. Data Analysis {#sec2dot6-antibiotics-09-00219}
------------------

The "Visualization of Similarities (VOS) viewer software" is widely used to graphically illustrate the bibliometric parameters in mapping networks, which allow easy visualization of critical elements \[[@B2-antibiotics-09-00219],[@B19-antibiotics-09-00219],[@B20-antibiotics-09-00219],[@B21-antibiotics-09-00219]\]. The current study used VOS to represent a graphical mapping of keywords as identified bibliometric analysis to identify the focus of research in recent decades.

2.7. Statistical Analysis {#sec2dot7-antibiotics-09-00219}
-------------------------

The descriptive data and associations of citation frequency, citation density, publication age, and CCI were analyzed using IBM SPSS Statistics^®^, version 22, using the Spearman rank test. The normality of data was checked using the Shapiro--Wilk test. To explore the difference between two or more independent groups, the Kruskal--Wallis test was performed. Post-hoc testing was performed to confirm the difference between variables. Mann--Kendall trend test was performed to determine increasing and decreasing time trends. A *p*-value of \< 0.05 was considered statistically significant.

3. Results {#sec3-antibiotics-09-00219}
==========

3.1. Bibliometric Parameters {#sec3dot1-antibiotics-09-00219}
----------------------------

The marked list of top 100 classics received a sum of 167,320 citations based on WoS, 165,947 citations based on ES, and 262,727 based on the GS database. The frequency of citations ranged from 940 to 11,051 (WoS), 1053 to 10,740 (ES), and 1162 to 20,041 (GS). Citation density is defined as the average number of citations/annum; it was calculated as 2742 (WoS), 2720 (ES), and 4307 (GS) for the 100 classics. "Antibiotic susceptibility testing by a standardized single disk method" was identified as the most cited "classic" with 11,051, 10,740, and 20,041 citations according to WoS, ES, and GS databases, respectively, with a citation density of 205 \[[@B22-antibiotics-09-00219]\]. "Antimicrobial peptides of multicellular organisms" was ranked second with 5685, 5668, 7994 citations according to WoS, ES, and GS databases, respectively, with a citation density of 316 \[[@B23-antibiotics-09-00219]\]. "Transformation of mammalian cells to antibiotic resistance with a bacterial gene under the control of the SV40 early region promoter" was ranked third with 3891, 2319, 3875 citations according to WoS, ES, and GS databases, respectively, with a citation density of 102 \[[@B24-antibiotics-09-00219]\]. The marked list of top 100 classics along with their citation frequency from WoS, ES, and GS databases, publication age, citation density, and CCI 2019 is presented in [Table 1](#antibiotics-09-00219-t001){ref-type="table"}. Shapiro--Wilk test revealed non-normal data on the citation frequency, citation density, and age of publication (years). [Figure 1](#antibiotics-09-00219-f001){ref-type="fig"}a shows a statistically significant upward trend of citation frequency was noted with the increase in publication age (R^2^ = 0.044, *p* = −0.012). [Figure 1](#antibiotics-09-00219-f001){ref-type="fig"}b shows a downward trend of citation density was noted with an increase in the age of publication (R^2^ = 0.304, *p* = −0.551), which was not statistically significant. The [Supplementary Figure S1](#app1-antibiotics-09-00219){ref-type="app"} illustrates the distribution of citation frequency over the last six decades.

3.2. Year of Publication {#sec3dot2-antibiotics-09-00219}
------------------------

Chronologically, the oldest classic with 60 years of publication age was published in 1959 \[[@B60-antibiotics-09-00219]\], and three articles with four years of publication age were published in 2015 \[[@B92-antibiotics-09-00219],[@B109-antibiotics-09-00219],[@B119-antibiotics-09-00219]\] made it to the "classics" list. Fifty articles were published during 2000--2009, followed by 22 published during 1990--1999, 13 published during 2010--2019, seven published during 1980--1989, five published during 1959--1969, and three published during 1970--1979. Nine articles were published in 1999, marking it the year of most publications. Interestingly, 63% of the articles were published within the last two decades. The highest number of "classics" were published between 2000 and 2009 (*n* = 50).

3.3. Methodological Design and Evidence Level (EL) {#sec3dot3-antibiotics-09-00219}
--------------------------------------------------

The distribution of the list based on methodological design is illustrated in [Figure 2](#antibiotics-09-00219-f002){ref-type="fig"}. Based on the level of evidence, 71 publications were graded as level-V, two were graded as level-IV, one belonged to level-III, four publications were graded as level-II, and 17 were graded as level-I. The evidence level and methodological design of five publications \[[@B24-antibiotics-09-00219],[@B52-antibiotics-09-00219],[@B60-antibiotics-09-00219],[@B77-antibiotics-09-00219],[@B111-antibiotics-09-00219]\] were not identified as full-text of the articles were not accessible through different electronic sources.

3.4. Contributing Authors, Institutions, and Countries {#sec3dot4-antibiotics-09-00219}
------------------------------------------------------

Robert E.W. Hancock was identified as the most contributing, authoring six classics, followed by Tomas Ganz, who contributed in four classics. A total of 513 authors contributed to the top 100 classics, among them 26 authors were contributed in two "classics" each. Complete texts for 95 publications were obtained, and five publications were not accessible through different institutions \[[@B24-antibiotics-09-00219],[@B52-antibiotics-09-00219],[@B60-antibiotics-09-00219],[@B77-antibiotics-09-00219],[@B111-antibiotics-09-00219]\]. Based on the institutional address of the corresponding author as retrieved from the ES database, individuals from 26 countries contributed to the "classic" articles. Among these, 69 scientific contributions were from the United States of America. Followed by 18 publications from Canada, 11 from Germany, and four from Sweden. Three publications originated from Belgium, China, and Israel. Two publications originated from Egypt, Denmark, and India. One publication originated from, Argentina, Croatia, Ecuador, France, Kenya, Korea, Netherlands, New Zealand, Pakistan, South Africa, South Korea, Spain, Tanzania, Thailand, United Kingdom, and Australia.

Among 246 international institutions, the greatest contribution to the "classic" articles was made by the University of Manitoba, Canada, in six classics followed by the Stanford University School of Medicine, USA, in five classics. "University of Washington, USA", "University of British Colombia, Canada", "The University of California at Los Angeles, USA", and "Harvard University, USA" contributed in four classics. "University of Kiel, Germany" and "University of California at San Diego, USA" contributed in three classics. "Robert Wood Johnson Medical School, USA", "Weizmann Institute of Science, Israel", "Emory University, Atlanta, Georgia, USA", "Laurentian University, Ontario, Canada", "Rush-Presbyterian-St. Luke's Medical Center, USA", "St. Agnes Medical Center, USA", "the Centers for Disease Control and Prevention, Atlanta, Georgia, USA", and "Veterans Affairs Palo Alto Health Care System, California, USA" contributed to two classics each.

3.5. Journal of Publication {#sec3dot5-antibiotics-09-00219}
---------------------------

The 100 classics were published across 63 different journals. [Figure 3](#antibiotics-09-00219-f003){ref-type="fig"} presents the list of journals in which the highest number of classics were published. The list of the remaining journals is available as [Supplementary Table S1](#app1-antibiotics-09-00219){ref-type="app"}.

3.6. Keywords {#sec3dot6-antibiotics-09-00219}
-------------

The most frequently occurring keywords in the top 100 classics were "anti-bacterial agents" and "antibiotic agent", followed by "antibiotic resistance", "anti-infective agent", and "antimicrobial". [Figure 4](#antibiotics-09-00219-f004){ref-type="fig"} is a graphical presentation of keywords arranged in a network of clusters. Colorful nodes represent the linkage of specific keywords to each cluster. [Table S2](#app1-antibiotics-09-00219){ref-type="app"} enlists the total number of index keywords and their frequency of occurrence based on the Elsevier Scopus database.

4. Discussion {#sec4-antibiotics-09-00219}
=============

The current study identified and analyzed the top 100 classics on antibiotics, antimicrobials, or antibacterial agents. Identification of any scientific contribution and inclusion in classics warrants the excellence and acclaimed acknowledgment by the relevant field experts, researchers, and scientists \[[@B12-antibiotics-09-00219]\]. Theoretically, a higher citation frequency of a publication indicates the quality of the research conducted as identified by the scientific community \[[@B122-antibiotics-09-00219]\]. Identification is imperative to study whether the classics have elaborated or explored the understanding of a problem and/or provided a comprehensive approach towards its solution, or whether the publication introduced a research trend or provided an expert opinion/summary on a topic of interest. The results of this study present the research perspective in the field of antibiotics, antimicrobials, or antibacterial agents for the last six decades. Additionlly, it illustrates key trends of research as well as clinical practice \[[@B2-antibiotics-09-00219],[@B8-antibiotics-09-00219]\].

The definition of "classics" largely depends on the research field/specialty to which the publication belongs. In some fields, 100 or more citations of a publication are considered enough to classify it as a "classic" \[[@B6-antibiotics-09-00219]\]. In perspective, the article ranked as 100th in the current study received 940 citations in comparison with the article ranked as 1st in the field of physics research in Korea that received 302 citations \[[@B123-antibiotics-09-00219]\] or with the article ranked as 1st in the dental caries research that received 2003 citations \[[@B19-antibiotics-09-00219]\]. For the current study, the publications receiving more than 400 citations can be considered classics. However, these publications will not make it to the top 100 due to the immense availability of the highly cited publications.

Web of Science was used as a benchmark database because it has citation metrics from 1945 to the present \[[@B124-antibiotics-09-00219]\]. A significant variance was observed when the citation metrics were cross-matched with other databases. The Elsevier Scopus database reports the citations dated back to 1996, which is a severe flaw while figuring out the most-cited papers. In contrast, the Google Scholar database counts the citations based on published articles, books, conference proceedings, thesis/dissertations, technical reports, and preprints, which explains the higher citation counts reported in the current study \[[@B2-antibiotics-09-00219]\].

The current study found a statistically significant correlation of the citation frequency with the age of publication, which is similar to the findings of a previous bibliometric analysis report \[[@B2-antibiotics-09-00219]\]. Although there was an upward trend of citations received by the classics to the age of publication \[[@B125-antibiotics-09-00219]\], the trend analysis of the influence of age of publication on the citation density revealed that certain topics after reaching maturity show a decrease in citation density. This change in trend can be also be noticed from the current citation index 2019.

It has been reported that the actual impact of a publication can only be assessed at least two decades after it has been published \[[@B2-antibiotics-09-00219],[@B4-antibiotics-09-00219],[@B17-antibiotics-09-00219]\]. Interestingly, this phenomenon has been observed in the current study as the most number of classics were published in 1999. However, it is noteworthy that with the changing trends of how published work is reviewed, the accessibility of literature has increased multifold, and research from around the world can be remotely reviewed without needing access to archives, libraries, and published paper journals. This debate is backed up by the current study, which observed that 63 classics were published during the last two decades. This finding indicates that in the current era of digital technology, classics might require lesser years to reach their maturity stage.

With the evolution of research, several guidelines have been introduced to fulfill the ever-growing need for organized reporting of observational studies \[[@B126-antibiotics-09-00219]\], laboratory studies \[[@B127-antibiotics-09-00219]\], clinical studies \[[@B128-antibiotics-09-00219]\], or reviews \[[@B129-antibiotics-09-00219]\]. These guidelines allow the scrutinization of scientific information and improve the quality and transparency of reports. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement is used to report systematic review and meta-analysis mainly focusing on evaluating randomized trials to provide the highest level of evidence. Surprisingly, the current study did not identify any systematic review of literature or meta-analysis, which made it to the list. The title of the study report is another key element which is stressed upon in various guidelines. It is entirely possible that some classics were not identified in the current study owing to how their titles were designed. A title should explicitly describe the methodology of study and key elements which identify the study to allow proper indexing of the article.

Keywords play an essential role in the discoverability of any published article \[[@B130-antibiotics-09-00219]\]. While searching any specific type of literature, scholars tend to methodically utilize search terms which are generally used in a specific field \[[@B131-antibiotics-09-00219]\]. In this study, prime examples of such terms are antibiotics, antibacterials, or antimicrobials. However, it was noted that keywords only appeared in articles published after 1995 and more so not mandatorily in every publication. It was noted that even though keywords might have been submitted in the journal database during submission of manuscripts, the published articles did not display the keywords \[[@B55-antibiotics-09-00219],[@B63-antibiotics-09-00219],[@B109-antibiotics-09-00219]\]. These incoherencies make the network analysis of keywords somewhat misleading and inconsistent with the actual data if we only rely on hand-searching. Therefore, the ES database was utilized to retrieve the relevant data to allow a presentable and fair network analysis.

5. Limitations {#sec5-antibiotics-09-00219}
==============

Firstly, a large amount of "classic" articles had to be excluded from the list as it was not considered possible to perform the bibliometric analysis of 500 or more articles in the current study. Therefore, the top 100 classics which achieved the maximum citations were selected for the present study. Secondly, the most recently published research papers are at a disadvantage irrespective of their content and quality, since they were outside the time window considered. Under this spectrum, it would not be wrong to say that the real impact of a research article cannot be accurately determined for at least five years post-publication.

6. Conclusions {#sec6-antibiotics-09-00219}
==============

This bibliometric analysis of the top 100 classics on antibiotics revealed that the increase in the age of publication positively influenced the citation frequency. Unlike times before 1996, the explosion of access to scientific articles in the current era of digital technology means that classics written more recently might require fewer years to reach their mature stage. In spite of substantial developments and advancements in this field/specialty in recent decades, there is a dearth of systematic reviews and meta-analyses among the top 100 publications. Keywords are the cornerstones of the discoverability of any manuscript and therefore, quality journals and publishers should mandate the inclusion of keywords in every publication to ensure maximum visibility of the publication across all databases.
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antibiotics-09-00219-t001_Table 1

###### 

List of 100 classics of antibiotics ranked based on their citation frequency according to the Web of Science, Scopus, and Scholar databases along with citation density and current citation index (2019).

  R ^1^   Author \[Reference\]                                               Year   CD ^2^   CCI ^3^ 2019   WoS ^4^   ES ^5^   GS ^6^
  ------- ------------------------------------------------------------------ ------ -------- -------------- --------- -------- --------
  1       Bauer, Kirby, Sherris, and Turck \[[@B22-antibiotics-09-00219]\]   1966   205      621            11,051    10,740   20,041
  2       Zasloff \[[@B23-antibiotics-09-00219]\]                            2002   316      398            5685      5668     7994
  3       Southern and Berg \[[@B24-antibiotics-09-00219]\]                  1982   102      3              3891      2319     3875
  4       Cowan \[[@B25-antibiotics-09-00219]\]                              1999   179      292            3749      4598     11203
  5       Sondi and Salopek-Sondi \[[@B26-antibiotics-09-00219]\]            2004   212      353            3397      3677     5471
  6       Brogden \[[@B27-antibiotics-09-00219]\]                            2005   224      302            3363      3353     4941
  7       Kumar et al. \[[@B28-antibiotics-09-00219]\]                       2006   214      291            2996      3185     5039
  8       Cohen et al. \[[@B29-antibiotics-09-00219]\]                       1972   59       17             2809      1775     3754
  9       Kim et al. \[[@B30-antibiotics-09-00219]\]                         2007   201      311            2615      2818     4164
  10      Stewart and Costerton \[[@B31-antibiotics-09-00219]\]              2001   130      217            2474      2602     4113
  11      Hancock and Sahl \[[@B32-antibiotics-09-00219]\]                   2006   170      139            2373      2391     3185
  12      Kovach et al. \[[@B33-antibiotics-09-00219]\]                      2006   167      244            2337      2319     3019
  13      Liu et al. \[[@B34-antibiotics-09-00219]\]                         1995   93       166            2332      2458     3571
  14      Dorman and Deans \[[@B35-antibiotics-09-00219]\]                   2000   110      177            2201      2407     4479
  15      Sharma et al. \[[@B36-antibiotics-09-00219]\]                      2009   188      240            2071      2269     3196
  16      Mah and O'Toole \[[@B37-antibiotics-09-00219]\]                    2001   108      183            2043      2127     3529
  17      Neu \[[@B38-antibiotics-09-00219]\]                                2003   116      119            1970      2071     3413
  18      Chopra and Roberts \[[@B39-antibiotics-09-00219]\]                 2001   104      230            1967      2026     3414
  19      Davies and Davies \[[@B40-antibiotics-09-00219]\]                  2009   178      312            1963      2037     3817
  20      Ganz \[[@B41-antibiotics-09-00219]\]                               2010   195      395            1952      1983     3115
  21      Zasloff \[[@B42-antibiotics-09-00219]\]                            2006   138      257            1935      1805     2643
  22      Kuemmerer \[[@B43-antibiotics-09-00219]\]                          1992   69       82             1930      2007     2734
  23      Dellit et al. \[[@B44-antibiotics-09-00219]\]                      1987   58       67             1915      1951     1732
  24      Wiegand et al. \[[@B45-antibiotics-09-00219]\]                     2010   187      146            1871      1898     2848
  25      Yeaman and Yount \[[@B46-antibiotics-09-00219]\]                   2007   144      146            1869      1846     2702
  26      Nathan et al. \[[@B47-antibiotics-09-00219]\]                      2003   108      169            1842      1246     2033
  27      Cushnie and Lamb \[[@B48-antibiotics-09-00219]\]                   2008   153      384            1839      2052     3983
  28      Goossens et al. \[[@B49-antibiotics-09-00219]\]                    2005   121      230            1811      1850     2904
  29      Sarmah et al. \[[@B50-antibiotics-09-00219]\]                      1983   47       31             1737      1817     2638
  30      Kumarasamy et al. \[[@B51-antibiotics-09-00219]\]                  2005   115      149            1726      1842     3071
  31      Mast et al. \[[@B52-antibiotics-09-00219]\]                        2005   115      70             1719      645      1868
  32      Rabea et al. \[[@B53-antibiotics-09-00219]\]                       2003   99       171            1689      1719     2523
  33      Anthonisen et al. \[[@B54-antibiotics-09-00219]\]                  2001   87       38             1650      1898     3065
  34      Magill et al. \[[@B55-antibiotics-09-00219]\]                      1987   49       57             1633      1601     2294
  35      Niederman et al. \[[@B56-antibiotics-09-00219]\]                   2014   260      337            1562      1893     2319
  36      Liang et al. \[[@B57-antibiotics-09-00219]\]                       1999   74       96             1552      1525     2168
  37      Zankari et al. \[[@B58-antibiotics-09-00219]\]                     2001   80       81             1518      1489     2039
  38      Gewirtz \[[@B59-antibiotics-09-00219]\]                            2006   108      102            1512      1550     2177
  39      Steers et al. \[[@B60-antibiotics-09-00219]\]                      2006   106      121            1482      596      1288
  40      Hirsch et al. \[[@B61-antibiotics-09-00219]\]                      1999   70       82             1474      1549     2469
  41      Jenssen et al. \[[@B62-antibiotics-09-00219]\]                     2012   184      484            1468      1462     2257
  42      Laxminarayan et al. \[[@B63-antibiotics-09-00219]\]                1959   24       1              1453      1454     2387
  43      Park et al. \[[@B64-antibiotics-09-00219]\]                        1995   58       30             1447      1511     2483
  44      Kohanski et al. \[[@B65-antibiotics-09-00219]\]                    2002   79       22             1421      1431     2062
  45      Shai \[[@B66-antibiotics-09-00219]\]                               2013   201      326            1410      1403     1990
  46      Boman \[[@B67-antibiotics-09-00219]\]                              2007   108      147            1405      1420     2100
  47      Hoiby et al. \[[@B68-antibiotics-09-00219]\]                       1999   66       65             1391      1395     2249
  48      Dethlefsen et al. \[[@B69-antibiotics-09-00219]\]                  2010   137      201            1372      1373     1981
  49      Hughes et al. \[[@B70-antibiotics-09-00219]\]                      2008   112      124            1347      1641     1790
  50      Nathan and Hibbs \[[@B71-antibiotics-09-00219]\]                   1999   64       99             1346      1230     1789
  51      Li et al. \[[@B72-antibiotics-09-00219]\]                          1991   46       25             1336      1399     1975
  52      Hidron et al. \[[@B73-antibiotics-09-00219]\]                      2008   111      72             1334      1418     2028
  53      Hammer et al. \[[@B74-antibiotics-09-00219]\]                      2008   110      146            1323      1492     3055
  54      Ong et al. \[[@B75-antibiotics-09-00219]\]                         2002   71       70             1286      1446     2058
  55      Herrero et al. \[[@B76-antibiotics-09-00219]\]                     2011   142      165            1280      1205     1714
  56      Burke \[[@B77-antibiotics-09-00219]\]                              1999   61       45             1278      1007     1773
  57      Kollef et al. \[[@B78-antibiotics-09-00219]\]                      2001   67       45             1269      1462     2254
  58      Freifeld et al. \[[@B79-antibiotics-09-00219]\]                    2000   63       45             1259      1493     2753
  59      Ibrahim et al. \[[@B80-antibiotics-09-00219]\]                     1990   41       46             1243      1405     2098
  60      Pigeon et al. \[[@B81-antibiotics-09-00219]\]                      1961   21       18             1234      1268     1917
  61      Bennett et al. \[[@B82-antibiotics-09-00219]\]                     2009   112      149            1232      704      1187
  62      Chambers and DeLeo \[[@B83-antibiotics-09-00219]\]                 1994   47       29             1213      1209     2058
  63      Davies \[[@B84-antibiotics-09-00219]\]                             1966   22       4              1194      1294     2295
  64      Cherepanov and Wackernagel \[[@B85-antibiotics-09-00219]\]         2010   117      184            1171      1157     1708
  65      Kong et al. \[[@B86-antibiotics-09-00219]\]                        1995   46       79             1154      1233     1741
  66      Hamblin and Hasan \[[@B87-antibiotics-09-00219]\]                  2000   58       33             1153      1226     1740
  67      Carter et al. \[[@B88-antibiotics-09-00219]\]                      1985   33       34             1152      1155     1677
  68      Ganz et al. \[[@B89-antibiotics-09-00219]\]                        2004   72       112            1152      1024     1628
  69      Ceri et al. \[[@B90-antibiotics-09-00219]\]                        1997   49       17             1135      1159     1716
  70      Classen et al. \[[@B91-antibiotics-09-00219]\]                     2005   75       46             1129      1318     2194
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